期刊文献+

甘精胰岛素联合那格列奈在继发性磺脲类失效的2型糖尿病中的应用 被引量:7

Effect of insulin glargine plus nateglinide in secondary sulfonylurea failure of type 2 diabetes
暂未订购
导出
摘要 目的探讨甘精胰岛素联合那格列奈治疗继发性磺脲类失效的2型糖尿病的疗效及安全性。方法 30例口服降糖药血糖控制不理想的2型糖尿病患者(GHbA1c≥9%)按1∶1随机分为甘精胰岛素治疗组和精蛋白锌重组赖脯胰岛素混和注射液(25R)对照组。观察空腹C肽(F-cp)及餐后C肽(P-cp),血糖控制、糖化血红蛋白(HbAlc)达标率和低血糖事件发生频率。结果治疗后两组F-cp及P-cp均较治疗前明显升高(P<0.05),两组FBG及餐后2h血糖均较基线水平明显下降(P<0.05),两组下降幅度及糖化血红蛋白(HbAlc)达标率比较差异无统计学意义(P>0.05),但治疗组低血糖发生率明显低于对照组。结论甘精胰岛素联合那格列奈治疗继发性磺脲类药物失效的2型糖尿病患者,可以良好地控制高血糖,部分恢复胰腺β细胞功能,且低血糖发生率显著降低,安全性好。 Objective To investigate the effect of insulin glargine combined nateglinide on controlling blood glucose level and the risk of hypoglycemia in type 2 diabetic patients with secondary sulfonylurea failure. Methods Thirty patients with glyeemia controlled ( GHbA1c≥9% ) were randomly divided into two groups. The treatment group ( 15 cases) was given insulin glargine plus nateglinide while the control group ( 15 cases) was given premixed insulin analogs ( Humanlog25). F - cp, P - cp, glucose control level, the success rate of GHbAle and hypoglycemia events were observed. Results The F - cp and P -cp of both groups were increased significantly ( P 〈 0. 05 ) ; while the fasting and postprandial blood glucose of both groups were decreased significantly ( P 〈 0. 05 ). There was no difference in the decrease range of blood glucose and success rate of GHbA1c between two groups ( P 〉 0.05 ). Compared to the control group, the incidence of hypoglycemia was lower in the treatment group. Conclusion The combination of insulin glargine plus nateglinide controls blood sugar concentration effectively and recovers the function of pancreatic β - cell partly in seeandary sulfonylurea failure of type 2 diabetic patients.
出处 《临床和实验医学杂志》 2012年第21期1705-1706,共2页 Journal of Clinical and Experimental Medicine
关键词 2型糖尿病 继发性磺脲类失效 甘精胰岛素 那格列奈 Type 2 diabetes mellitus Secondary sulfonylurea failure Insulin glargine Nateglinide
  • 相关文献

参考文献7

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 2Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus [ J ]. Clin Ther, 2004,26 (6) : 889 - 901.
  • 3Kurtzhals P, Schaffer L, SФrensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use [ J ]. Diabetes, 2000,49 (6) :999 - 1005.
  • 4Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta - cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel -group trial [ J ]. Lancet, 2008,371 (9626) : 1753 - 1760.
  • 5餐后高血糖治疗策略专题研讨会报道[J].中国糖尿病杂志,2007,15(3). 被引量:3
  • 6杨文英.磺脲类药物受体及其临床意义[J].国外医学(内分泌学分册),2003,23(4):230-232. 被引量:10
  • 7Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes[J]. Diabetes Care, 2005,28(2) :254 -259.

共引文献2795

同被引文献60

  • 1刘宝萍.重组甘精胰岛素注射液国产制剂(长秀霖)联合口服降糖药治疗2型糖尿病的疗效和安全性分析[J].医学信息(医学与计算机应用),2014,0(1):350-350. 被引量:4
  • 2张秀梅,牛建生,师福香,张玲,陈欣.那格列奈联合甘精胰岛素或中效人胰岛素治疗2型糖尿病的比较[J].延安大学学报(医学科学版),2009,7(3):26-28. 被引量:8
  • 3International Diabetes Federation. Diabetes Atlas (sixth edition). 2013.
  • 4IIag LL, Kerr L, Malone JK, et al. Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evident-based Comparison. Clin Ther, 2007, 29(6 pt1): 1254-1270.
  • 5Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract, 2008, 81(2): 184-189.
  • 6Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 Basal + Prandial Insulin Analogue Mixture with a Basal Insulin Analogue, Both Plus Metformin, in the Achievement of Target HbA1c and Pre- and Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes: A Multinational, 24-Week, Randomized, Open-Label, Parallel-Group Comparison. Clin Ther, 2007, 29(11): 2349-2364.
  • 7Kazda C, Hülstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications, 2006, 20(3): 145-152.
  • 8Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care, 2008, 31(1): 20-25.
  • 9Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes and Metab, 2010, 12(11): 967-975.
  • 10Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care, 2009, 32(6): 1007-1013.

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部